News


08/25/14, Cardiovascular diseases New Data on Xarelto® (Rivaroxaban) from Bayer accepted for ESC Congress 2014 Hot Line Session Results from X-VeRT, the first prospective study of a novel oral anticoagulant in patients with atrial fibrillation undergoing cardioversion will be presented during ESC Congress 2014 Hot Line Session / Sub-analyses from ROCKET AF and ATLAS ACS 2-TIMI 51 to provide further insights into clinical utility of Xarelto / Independently, the Thrombosis Research Institute (TRI) will present data from the GARFIELD AF Registry, an academic research initiative, supported through an unrestricted educational grant from Bayer more

EU verification logo for reputable online pharmacies

From July the European Commission is introducing a Europe-wide logo to help customers identify legitimate internet providers. more

"Young people want self-determination": Parliamentary Evening in Berlin

What do young people worldwide wish for the future?

more

Taking the "neglect" out of "Neglected Tropical Diseases":

Two years after the London Declaration, tremendous progress is apparent more

Bayer Clinical Trials

Information about Bayer sponsored clinical studies is available at

Facebook

Facebook Banner

Follow us on Facebook

more

Links


http://www.bayerpharma.com/en/index.php

Copyright © Bayer Pharma AG